Malignant Hyperthermia
Authors' conclusion
Increasing use of inhalational anesthetics in the ICU underscores the need for enhanced education on the diagnosis and management of MH to ensure optimal patient sedation care and safety.
Study context
- Population
- Critically ill patients with malignant hyperthermia (MH), ICU and perioperative settings
Main finding
As reported in the abstract
- MH: severe reaction triggered by inhalational volatile anesthetics and succinylcholine in genetically susceptible patients
- Early onset (min to hr) rise in temperature, hypercarbia and muscular rigidity after triggering medications; potential complications coagulopathy, rhabdomyolysis, AKI
- Acute management: coordinated multidisciplinary team; dantrolene, active cooling, hyperventilation
- All suspected reactions should be followed up at a specialized MH testing center (muscle contracture and genetic testing); implications for future anesthetic exposure for patient and family
Original publication
Malignant Hyperthermia. Crit Care Med. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →